Pulmonary Vascular Limitation After COVID: What is known so far?- Adriano Tonelli, MD

Autism Spectrum Disorder and Epilepsy – Part 1. Gregory Holmes, M.D. and Marvin Natowicz, M.D., Ph.D

Autism Spectrum Disorder and Epilepsy –Part 2. Gregory Holmes, M.D. and Marvin Natowicz, M.D., Ph.D.

Optimizing outcomes in IMIDs: Focus on Co-Morbidities

Key Issues in the Differential Diagnosis of Vasculitis

CNS vasculitis

Old Diseases, New Developments

Old Diseases, New Treatments

Advances in Immunology for the Non-Immunologist: The human immune response at 30,000 feet

GLP-1 RA Therapy in T2D - Vinni Makin, MD, Kevin M. Pantalone, DO, Pratibha PR Rao, MD, MPH

Evidence-based Management of T2D with ASCVD, CKD, or HF

SGLT-2 Inhibitors- Vinni Makin, MD, Kevin M. Pantalone, DO, Pratibha PR Rao, MD, MPH

Rheum/Derm Overlap Diseases Immunologic Responses- Cassandra Calabrese, DO, Samantha Polly, MD

Rheum/Derm Overlap Diseases, IMIDs Involving the Skin- M. Elaine Husni, MD, MPH

Treatment of Psoriatic Disease

Update in Treatment Medical Dermatologic Diseases

Metabolic Interventions in PAH- Anna Hemnes, MD

Heterogeneity of Metabolic Endo-Phenotypes of PAH - Samar Farha, MD

Pulmonary Vascular Limitation After COVID: What is known so far?- Adriano Tonelli, MD

PH in ILD: Finally some hope?- Kristin Highland, MD

Chronic Thromboembolic PH- Alice Goyanes, MD

PH in HFpEF: What can we do?- Sanjeeb Bhattacharya, MD

Emerging Therapeutics for PAH- Bradley Maron, MD

Risk Stratification and Current Treatment Algorithm- Anthony R. Cucci, MD

Advances in the Diagnostic and Hemodynamic Evaluation of PH- Bradley Maron, MD